PharmaReports: Psychiatric, Addictive & Sleep Disorders
LeadDiscovery offers full reports in selected areas of the pharmaceutical and biotech sector.
Each of the reports below has been especially selected by LeadDiscovery. Browse the reports or try our search engine.
This channel focuses on the main psychiatric diseases such as depression, bipolar disease, anxiety and schizophrenia although reports focusing on neuroelectrophysiology (for example epilepsy) are also included here. Likewise reports relating to addictive, sleep and attention deficit disorders are also included here.
Showing results 51 - 100 of 113
- Two pharmaceutical reports for the price of one - End of year offer
- UpdatesPlus Nicotinic Receptors - Current Research and Development - February 2009
- Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
- Smoking Cessation Report, 2009-2024
- UpdatesPlus Nicotinic Receptors - Current Research and Development - March 2009
- New Approaches to Pharma Research and Development: Evolving strategies to rejuvenate Research and Development efficiency
- UpdatesPlus Nicotinic Receptors - Current Research and Development - June 2009
- UpdatesPlus Nicotinic Receptors - Current Research and Development - July 2009
- World Sleep Disorders Market Analysis 2009-2024
- UpdatesPlus Nicotinic Receptors - Current Research and Development - September 2009
- Monoclonal Antibody Therapeutics 2009-2024
- World Generics Market 2009-2024
- The World Market for Biosimilars and the Potential for US Follow-on Biologics
- Global Pharmaceutical Biotech Market 2010-2025
- What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and Other Vaccine Targets in the 2010-2020 Pipeline
- World Smoking-Cessation Drug Market 2010-2025
- The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
- Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline
- Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
- Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015
- Schizophrenia - Drug Pipeline Analysis and Market Forecasts to 2015
- Bipolar Disorder - Drug Pipeline Analysis and Market Forecasts to 2015
- Addiction Control - Drug Pipeline Analysis and Market Forecasts to 2015
- World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
- Neurology Devices Market Outlook in United States to 2016 - Neurostimulation Devices, Interventional Neurology and Others
- Neurology Devices Market Outlook in Japan to 2016 - Neurostimulation Devices, Interventional Neurology and Others
- CNS Clinical Trials: World Market Prospects 2011-2026
- US Pharmaceutical Market Outlook 2011-2021
- Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
- UpdatesPlus Nicotinic Receptors - Current Research and Development - March 2011
- R&D Trends: Depression
- Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
- Pharmaceutical Key Trends 2011 – Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
- R&D Trends: Depression - Pipeline characterized by its depth and diversity
- R&D Trends: Bipolar Disorders - Developments in schizophrenia dictate trends in diminutive bipolar disorders pipeline
- UpdatesPlus Nicotinic Receptors and Addiction - Current Research and Development - April/May 2011
- Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
- Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
- Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
- Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
- Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies
- Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Latuda (Schizophrenia) – Analysis and Forecasts to 2020
- undefinedInvega (Schizophrenia) – Analysis and Forecasts to 2020
- Saphris (Schizophrenia) – Analysis and Forecasts to 2020
- Zicronapine (Schizophrenia) – Analysis and Forecasts to 2020
- Geodon (Schizophrenia) – Analysis and Forecasts to 2017
- Clozapine (Schizophrenia) – Analysis and Forecasts to 2020
Browse our theraputic areas for other entries:
- Oncology
- Cancer Immunotherapy
- Immunology & Inflammatory Diseases
- Infectious Diseases
- Psychiatric, Addictive & Sleep Disorders
- Pain
- Neurodegenerative & Neuroelectrophysiological Disorders
- Metabolic & Hormonal Disorders
- Cardiovascular Disorders
- GenitoUrinary Tract Disorders
- Technology
- Diagnostics & Devices
- Other Theraputic Areas, Pharmaceutical Strategy and Development